The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (A).
E. Muñoz-Couselo
No relevant relationships to disclose
J. M. Perez-Garcia
No relevant relationships to disclose
C. Saura
No relevant relationships to disclose
M. Vidal
No relevant relationships to disclose
M. Bellet Ezquerra
No relevant relationships to disclose
J. Balmaña
No relevant relationships to disclose
B. Graña
No relevant relationships to disclose
P. Gomez Pardo
No relevant relationships to disclose
L. De Mattos-Arruda
No relevant relationships to disclose
S. Di Cosimo
No relevant relationships to disclose
S. Muñoz
No relevant relationships to disclose
O. Vidal
No relevant relationships to disclose
B. Garcia Castro
No relevant relationships to disclose
R. Espallargas
No relevant relationships to disclose
V. Esteban
No relevant relationships to disclose
J. Tabernero
No relevant relationships to disclose
J. Baselga
No relevant relationships to disclose
J. Cortes
No relevant relationships to disclose